

[Leuprorelin](#)

Essential medicine status

Section:

[8. Immunomodulators and antineoplastics](#) [8.2. Antineoplastics and supportive medicines](#) [8.2.4. Hormones and antihormones](#)

ATC codes: [L02AE02](#)

Indication

Malignant neoplasms of prostate ICD11 code: [2D32.Z](#)

INN

Leuprorelin

Medicine type

Chemical agent

List type

Complementary

Formulations

Parenteral > General injections > IM: 7.5 mg in prefilled syringe ; 22.5 mg in prefilled syringe

EML status history

First added in 2015 ([TRS 994](#))

Changed in 2021 ([TRS 1035](#))

Sex

Male

Age

Adolescents and adults

Therapeutic alternatives

[goserelin](#) (ATC codes: [L02AE03](#))

[triptorelin](#) (ATC codes: [L02AE04](#))

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Tags

Cancer

Wikipedia

[Leuprorelin](#)

DrugBank

[Leuprorelin \(Leuprolide\)](#)

Summary of evidence and Expert Committee recommendations



Following the review of square box listings on the EML and EMLc, the Expert Committee recommended goserelin and triptorelin be specified as therapeutic alternatives under the square box listing for leuprorelin on the EML.